T cell receptor V gamma 9 V delta 2 (TCR Vγ9Vδ2)

T cell receptor V gamma 9 V delta 2 (TCR Vγ9Vδ2) is a highly conserved γδ T cell receptor that is the dominant circulating γδ TCR in human peripheral blood. It recognizes non-peptide phosphoantigens, such as isopentenyl pyrophosphate (IPP) and (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP), in a mechanism that is independent of classical major histocompatibility complex (MHC) molecules and instead depends on butyrophilin family members, primarily BTN3A1 and BTN2A1[1][2][4][7]. Engagement of the TCR by these ligands triggers potent cytotoxicity, cytokine production, and can endow these T cells with antigen-presenting functions. Vγ9Vδ2 T cells have important roles in immune surveillance against infections, especially microbial, and in antitumor immunity. They are regarded as promising targets for immunotherapies in cancer and infectious diseases, and can be pharmacologically expanded and activated by drugs such as aminobisphosphonates (e.g., zoledronate) in combination with cytokines (e.g., IL-2)[5][6]. However, their functions are vulnerable to suppression in cancer and chronic infectious contexts, and excessive activation carries risks like cytokine release syndrome and possible autoimmunity[2][6].

Other names

Vγ9Vδ2 TCRgamma delta T cell receptor Vγ9Vδ2γδ TCR Vγ9Vδ2Vγ9Vδ2 T cell receptorVγ2Vδ2 T cell receptor

Activation or expansion of Vγ9Vδ2 T cells increases cytotoxic response against tumor or infected cells via phosphoantigen-induced TCR signaling Modulation of immune response by cytokine secretion or antigen presentation Drugs (e.g., zoledronate) induce accumulation of endogenous phosphoantigen (IPP) in target cells, triggering TCR signaling and immune cell activation